IRIS
FRANCINI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.197
EU - Europa 10.994
AS - Asia 7.057
SA - Sud America 1.079
AF - Africa 245
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 15
Totale 34.619
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.021
CN - Cina 2.691
GB - Regno Unito 2.489
SG - Singapore 2.156
RU - Federazione Russa 2.086
IE - Irlanda 1.577
UA - Ucraina 1.188
BR - Brasile 911
SE - Svezia 884
FR - Francia 831
DE - Germania 737
VN - Vietnam 586
HK - Hong Kong 571
IT - Italia 558
KR - Corea 378
FI - Finlandia 362
IN - India 164
ZA - Sudafrica 123
CA - Canada 93
BD - Bangladesh 69
AR - Argentina 60
TR - Turchia 57
ES - Italia 54
IQ - Iraq 52
MX - Messico 48
NL - Olanda 42
PL - Polonia 39
PK - Pakistan 38
ID - Indonesia 36
JP - Giappone 33
SA - Arabia Saudita 33
NG - Nigeria 31
AU - Australia 27
BE - Belgio 25
MA - Marocco 25
EC - Ecuador 24
CI - Costa d'Avorio 23
CL - Cile 22
UZ - Uzbekistan 21
VE - Venezuela 20
AT - Austria 18
PH - Filippine 17
CZ - Repubblica Ceca 16
IR - Iran 16
AE - Emirati Arabi Uniti 15
EU - Europa 15
NP - Nepal 15
MY - Malesia 14
CO - Colombia 11
KE - Kenya 11
DK - Danimarca 10
JO - Giordania 10
LT - Lituania 10
PE - Perù 9
TH - Thailandia 9
AZ - Azerbaigian 8
BG - Bulgaria 8
JM - Giamaica 8
OM - Oman 8
PY - Paraguay 8
TW - Taiwan 8
UY - Uruguay 8
LB - Libano 7
RO - Romania 7
TN - Tunisia 7
EG - Egitto 6
KZ - Kazakistan 6
AL - Albania 5
BY - Bielorussia 5
CR - Costa Rica 5
IL - Israele 5
NZ - Nuova Zelanda 5
PA - Panama 5
TT - Trinidad e Tobago 5
BH - Bahrain 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
HU - Ungheria 4
MD - Moldavia 4
PS - Palestinian Territory 4
PT - Portogallo 4
AM - Armenia 3
BO - Bolivia 3
CH - Svizzera 3
EE - Estonia 3
GR - Grecia 3
GY - Guiana 3
HR - Croazia 3
KW - Kuwait 3
MM - Myanmar 3
QA - Qatar 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AO - Angola 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CD - Congo 2
CG - Congo 2
CY - Cipro 2
Totale 34.585
Salva come PNG Salva come JPEG
Città #
Southend 2.156
Dallas 1.851
Fairfield 1.577
Dublin 1.560
Singapore 1.216
Ashburn 1.094
Chandler 987
Jacksonville 962
Woodbridge 804
Wilmington 669
Seattle 644
Houston 603
Santa Clara 599
Beijing 585
Moscow 573
Hong Kong 545
Cambridge 493
Hefei 452
Seoul 375
San Jose 366
Nanjing 353
Ann Arbor 351
Princeton 320
The Dalles 289
New York 281
Los Angeles 186
Ho Chi Minh City 177
Lauterbourg 177
Siena 156
San Mateo 151
Hanoi 140
Boardman 136
Helsinki 121
Nanchang 117
Munich 113
Johannesburg 106
Buffalo 96
San Diego 92
São Paulo 66
Shanghai 63
Council Bluffs 61
Dong Ket 61
Changsha 52
Hebei 51
Shenyang 51
Tianjin 50
Kunming 47
Redondo Beach 47
Norwalk 45
Turku 43
Bengaluru 41
Milan 41
Frankfurt am Main 40
London 38
Columbus 37
Toronto 37
Jiaxing 36
Orem 36
San Francisco 35
Rio de Janeiro 33
Málaga 32
Warsaw 32
Abuja 29
Lancaster 29
Tokyo 29
Guangzhou 28
Zhengzhou 27
Amsterdam 25
Brooklyn 25
Brussels 25
Ningbo 25
Chennai 24
Hangzhou 24
Montreal 24
Abidjan 22
Belo Horizonte 22
Düsseldorf 22
Haiphong 22
Da Nang 21
Jinan 21
Tashkent 21
Baghdad 20
Chicago 20
Menlo Park 20
Boston 19
Fremont 19
Nuremberg 19
Washington 19
Atlanta 18
Manchester 18
Biên Hòa 16
Dhaka 16
Stockholm 16
Auburn Hills 15
Denver 15
Philadelphia 15
Porto Alegre 15
Rome 15
Campinas 14
Phoenix 14
Totale 23.336
Salva come PNG Salva come JPEG
Nome #
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 347
Survival following early-stage colon cancer: An ACCENT-based comparison of patients versus a matched international general population 329
Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma 321
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 308
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma 304
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. 300
A62Effectiveness and resulting surgical behavior after neoadjuvant chemotherapy in locally advanced breast cancer: our experience 285
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid 284
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 281
Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation 279
70 Tumor associated hypercalcemia 278
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 262
Peptidi epitopici immunogenici del CEA da utilizzare nella chemio-immunoterapia del carcinoma del colon-retto e della mammella. 261
A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients 256
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer 256
Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases 254
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer. 252
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 250
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience 247
A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate camcer metastates, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2 246
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 242
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 241
Dendritic cell-cediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro 240
Bioactivity of GM-CSF and IL-2 in cancer patients 234
Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey 233
Folinic Acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer 229
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 225
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients 224
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer 223
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity 223
Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study 221
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mytomicin C 218
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer 216
A Poly-epitopic peptide vaccine against the thymidylate synthase (TS). A synergistic therapeutic combination with fluoropyrimidine-based-chemotherapy 216
A five-day treatment of tumor-induced hypercalcemia by intravenous amino-hexane (AHBP) or aminobutane (ABBP) bisphosphonate 214
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 214
Ecto 5'-nucleotidase in B-cell lymphocytic leukemia 213
Quality of life in advanced colorectal cancer 211
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer 210
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients with fractioned cisplatinum, oral etoposide and bevacizumab: phase IB/II study 209
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 209
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 209
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial) 206
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 205
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 204
Doxetacel and epirubicin compared with doxetacel and prednisone in advanced castrate-resistant prostate cancer: a randomized phase II study 204
Hepatoid gastric carcinoma. A case report 204
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. 203
GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. 203
Circulating levels of immunoreactive peptides and steroid hormones in bronchogenic carcinoma 202
Virosoma dell'influenza immunoricostituito (IRIV) contenente il gene per CD40L come immunoprotettore tumorale CEA-specifico e usi immunogenici di esso. 200
Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens 199
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. 199
Analgesic activity and side effects of different calcitonins in man 199
Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate 197
Chemo-immunotherapy of colo-rectal cancer: Drug induced antigen specific cell-mediated immune response in vitro and in cancer patients 196
Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastases 193
Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. 193
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies 192
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials 191
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study: TILs for ADJ-untreated stage II colon cancer 191
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 190
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 189
Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer. 188
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 187
Immune-regulatory (FoxP3+)-T-cell tumor infiltration status is predictive of benefit from chemo-immunotherapy with gemcitabine, oxaliplatin, 5FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 186
Urinary excretion of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate in malignancy 185
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? 185
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials 183
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane 182
Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients 182
Acute effects of salmon, human and porcine calcitonin on plasma calcium and cyclic AMP levels in man 181
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer 181
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. 179
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. 178
Palliative chemotherapy for relief of subocclusive symptoms 177
Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation 177
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. 177
Squamocellular gallbladder carcinoma associated with multiple small pigment stones long term after total gastrectomy 176
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy 174
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 173
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care 173
Is endocrine hyperactivity a favourable prognostic factor in the chemotherapic treatment of bronchogenic carcinoma? 173
Seasonal variation in urinary excretion of cyclic AMP in healthy people 171
Analgesic effect of salmon calcitonin nasal pray on bone pain 170
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. 169
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803 169
Hypercalcemia and urinary excretion of cyclic AMP in bronchogenic carcinoma 168
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel 167
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen 167
Osteoblastic metastases: Metabolic and morphologic aspects 167
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. 165
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma 164
Hyperprogressive disease in advanced cancer patients treated with nivolumab: a case series study 164
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study 163
THYMIDYLATE SYNTHASE RELATED POLYEPITOPE PEPTIDE CANCER THERAPEUTICS 162
Weekly epirubicin in patients with hormone-resistant prostate cancer 161
Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes 161
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials 161
PTH-RP related peptide cancer therapeutics. 160
Totale 21.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.587
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.587
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021811 0 0 0 0 0 0 0 0 0 233 316 262
2021/20222.348 176 305 197 184 97 61 98 94 125 253 234 524
2022/20233.532 232 205 442 530 349 776 60 319 386 59 115 59
2023/20242.265 111 58 168 69 63 744 757 39 3 47 48 158
2024/20254.466 109 279 300 258 530 206 74 219 382 167 526 1.416
2025/202610.031 883 1.778 1.365 1.055 1.950 433 1.259 338 397 573 0 0
Totale 34.765